Therapeutic Effectiveness and Safety of Mesotherapy in Patients with Osteoarthritis of the Knee

Table 1

Clinical features of the included patients.

	Group A		Group B
Gender
Male	3		4
Female	21		22
Age	57.2 ± 3.4		61.4 ± 6.8
Course of disease (years)	6 ± 4.6		9 ± 7.1
Inflammation
Acute phase	17		10
Chronic phase	7		16
Body mass index^#	25.3 ± 3.6		24.7 ± 4.8
PPIs use^§	5 (20.8%)		0		p < 0.05
Supplementary treatment^§§	14 (58.3%)		4 (15.4%)		p < 0.01
	Pretreatment	Posttreatment	Pretreatment	Posttreatment
Laboratory test
CRP	16.62 ± 6.01	10.25 ± 3.50	16.43 ± 5.73	9.50 ± 3.46	p < 0.05
Group A versus Group B	p < 0.05
ESR	42.64 ± 11.77	29.31 ± 8.14	42.34 ± 10.68	21.77 ± 6.42
Group A versus Group B	p > 0.05

BMI: body mass index = weight/height². ^§PPIs: proton pump inhibitors. ^§§Supplementary treatment: a request for oral NSAIDs after 3 months of treatment in Group A or an extra session of mesotherapy in Group B.